Results 71 to 80 of about 957 (170)

Pharmacokinetics of sulbactam-durlobactam in patients with Acinetobacter baumannii ventriculitis: a report of two cases

Antimicrobial Agents and Chemotherapy
ABSTRACT Two adult patients with ventriculitis due to Acinetobacter baumannii were treated with intravenous sulbactam-durlobactam as a part of a combination regimen. Penetration into the central nervous system was estimated (by
Nazanin Pouya, Natalie A. Finch, Alejandro Granillo, Adarsh Bhimraj, Vincent H. Tam, William R. Miller   +5 more
openaire   +3 more sources

Efficacy and safety of antibiotics in the treatment of multidrug-resistant Acinetobacter baumannii infections: A systematic review and Bayesian network meta-analysis

Journal of Global Antimicrobial Resistance
: Objectives: This study aims to compare the efficacy and safety of antimicrobial regimens for multidrug-resistant Acinetobacter baumannii (MDR A. baumannii) infections using a Bayesian network meta-analysis (NMA).
Binh Van Tran, Phi Yen Huynh, Tu Tuan Tran, Bao Bui Hoang, Ka-Wai Tam   +4 more
doaj   +1 more source

Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

Future Microbiology
Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC) in patients 18 years of age and older.
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye   +4 more
openaire   +2 more sources

In vitro interactions of sulbactam/durlobactam in combination with meropenem, ceftazidime/avibactam, piperacillin/tazobactam, cefiderocol and fosfomycin against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates

: We evaluated in vitro activity of sulbactam/durlobactam in combination with different antimicrobials against Carbapenem-Resistant Acinetobacter baumannii (CRAB) clinical isolates with different susceptibility profiles, including sulbactam/durlobactam ...
Zocche, Giulia, Lewis, Russell E, Tascini, Carlo, Gaibani, Paolo, Bianco, Gabriele   +4 more
core   +1 more source

Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Microorganisms
Acinetobacter baumannii complex (ABC) can result in a panoply of severe syndromes, including pneumonia and septic shock. Options available for treating infections caused by ABC and, more importantly, by carbapenem-resistant ABC (CRAB) are limited because
Noayna Arshad, Wael Azzam, Marya D. Zilberberg, Andrew F. Shorr   +3 more
doaj   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Resistance to sulbactam/durlobactam in carbapenem-resistant Acinetobacter baumannii in treatment-naive setting: in vitro data and genomic insights from Italian bloodstream isolates

Objectives: This study evaluated the in vitro activity of sulbactam/durlobactam and comparators against carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream isolates from Italy and investigated genomic mechanisms underlying resistance. Methods:
Boattini, Matteo, Biffignandi, Gherard Batisti, Vumbaca, Michela, Comini, Sara, Costa, Cristina, Gaibani, Paolo, Bianco, Gabriele   +6 more
core   +1 more source

Μελέτη νεότερου αναστολέα β-λακταμασών σε ανθεκτικά στις καρβαπενέμες στελέχη Acinetobacter baumannii

, 2022
ΕΙΣΑΓΩΓΗ: Το Acinetobacter baumannii αποτελεί κύρια αιτία λοιμώξεων σχετιζόμενων με χώρους υγειονομικής περίθαλψης, εξαιτίας της επιμονής του ως αποικιστή στο νοσοκομειακό περιβάλλον και της ικανότητας του να αποκτά υψηλού επιπέδου αντοχή.
Petropoulou Dimitra, Πετροπούλου Δήμητρα   +1 more
core   +1 more source

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics

Pathogens
The growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics.
Maria Sargianou, Panagiotis Stathopoulos, Christos Vrysis, Iva D. Tzvetanova, Matthew E. Falagas   +4 more
doaj   +1 more source

Self‐Assembling Hydrogel‐Based Controlled Delivery of Sulbactam–Durlobactam and Cefiderocol Against Carbapenem‐Resistant Acinetobacter baumannii

Carbapenem‐resistant Acinetobacter baumannii (CRAB) has emerged as a major global healthcare threat because of its multidrug resistance, biofilm‐forming ability, and ...
R. Sowmya, Krithika Shree Sivasuriyan, S. Karthick Raja Namasivayam, Amrish Varshan G.S   +3 more
core   +1 more source